{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8095"},{"groupId":"OG001","value":"0.5882"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"Proportion of patients in hematologic, molecular, and cytogenetic remission at end of consolidation, course 3 and 4 are reported. Patients were determined to be in remission by all three criteria.","groups":[{"description":"WBC\\<10,000/MicroLiter","id":"OG000","title":"Standard Risk"},{"description":"WBC\\>=10,000/MicroLiter","id":"OG001","title":"High Risk"}],"paramType":"NUMBER","populationDescription":"Patients who were ineligible (n=6), inevaluable (n=1), or who electively withdrew during Induction (n=4) were excluded.","reportingStatus":"POSTED","timeFrame":"End of consolidation, course 3; up to 7 months (for Standard Risk) or end of consolidation, course 4; up to 9 months (for High Risk)","title":"Hematologic, Molecular, and Cytogenetic Remission Rate","type":"SECONDARY","unitOfMeasure":"Proportion of participants"}